Heidelberg Pharma is a biopharmaceutical company specializing in the research, development, and production of antibody-drug conjugates (ADCs) for oncology. The company utilizes a proprietary ATAC technology platform based on the toxin amanitin to develop highly specific cancer therapies. In addition to its own product pipeline, the company provides services to third parties and licenses its intellectual property and technologies to partners. Heidelberg Pharma operates as a group headquartered in Ladenburg and is listed in the Prime Standard of the Frankfurt Stock Exchange.
Erforschung, Entwicklung, Herstellung, Zulassung und Vertrieb von Arzneimitteln und Diagnostika, vorzugsweise im Bereich der Onkologie, auch im Wege der Erbringung von Dienstleistungen für Dritte, sowie Ein- und Auslizenzierung darauf basierender Schutzrechte.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 728735 (as of 21 November 2026)
| Name | Type | City |
|---|---|---|
| Dongzhou Liu | Vorstand | Monroe |
| Peter Willinger | Vorstand | Walldorf |
| Company | Location |
|---|---|
| Ladenburg | |
| Ladenburg | |
| Ladenburg |
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 728735 (as of 21 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €6,849,257 | -€19,381,995 | €60,720,317 | 36 |
| 2023 | €9,858,912 | -€20,346,486 | €70,353,032 | — |
| 2021 | €1,749,829 | -€26,138,702 | €21,732,119 | 11 |
| 2020 | €8,487,938 | -€18,369,038 | €19,608,792 | 79 |
| 2018 | — | — | €0 | 62 |
Source: German Company Register (Unternehmensregister) · Group accounts
Sign in to download data
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 728735 (as of 21 November 2026)